JP6517827B2 - イソインドリン組成物および神経変性疾患の治療方法 - Google Patents
イソインドリン組成物および神経変性疾患の治療方法 Download PDFInfo
- Publication number
- JP6517827B2 JP6517827B2 JP2016549224A JP2016549224A JP6517827B2 JP 6517827 B2 JP6517827 B2 JP 6517827B2 JP 2016549224 A JP2016549224 A JP 2016549224A JP 2016549224 A JP2016549224 A JP 2016549224A JP 6517827 B2 JP6517827 B2 JP 6517827B2
- Authority
- JP
- Japan
- Prior art keywords
- sigma
- alkyl
- beta
- pharmaceutically acceptable
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(CCc(cc1)cc(OC(F)(F)F)c1O)N(C1)Cc2c1cccc2S(C)(=*)=O Chemical compound CC(C)(CCc(cc1)cc(OC(F)(F)F)c1O)N(C1)Cc2c1cccc2S(C)(=*)=O 0.000 description 2
- ISQAPFMBJFZOLG-UHFFFAOYSA-N CC(C)(C)Oc(cc(CCC(C)(C)N(C1)Cc2c1ccc(S(C)(=O)=O)c2)cc1)c1O Chemical compound CC(C)(C)Oc(cc(CCC(C)(C)N(C1)Cc2c1ccc(S(C)(=O)=O)c2)cc1)c1O ISQAPFMBJFZOLG-UHFFFAOYSA-N 0.000 description 1
- KQEMZULFPCJGFL-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(NC(F)(F)F)c1O)N(Cc1ccc2)Cc1c2S(C)(=O)=O Chemical compound CC(C)(CCc(cc1)cc(NC(F)(F)F)c1O)N(Cc1ccc2)Cc1c2S(C)(=O)=O KQEMZULFPCJGFL-UHFFFAOYSA-N 0.000 description 1
- PHQRKBIXTTYDLO-UHFFFAOYSA-N CC(C)(CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cccc2C(CN1CCNCC1)=O Chemical compound CC(C)(CCc(cc1)cc(OC)c1O)N(C1)Cc2c1cccc2C(CN1CCNCC1)=O PHQRKBIXTTYDLO-UHFFFAOYSA-N 0.000 description 1
- QSCBMVHTDSJVEE-UHFFFAOYSA-N CC(C)(CCc(cc1)ccc1F)N(C1)Cc2c1cc1OCOc1c2 Chemical compound CC(C)(CCc(cc1)ccc1F)N(C1)Cc2c1cc1OCOc1c2 QSCBMVHTDSJVEE-UHFFFAOYSA-N 0.000 description 1
- YXISLLAVLYFJLK-UHFFFAOYSA-N CC(C)(CCc(cc1OC)ccc1OCCO)N(C1)Cc2c1cccc2F Chemical compound CC(C)(CCc(cc1OC)ccc1OCCO)N(C1)Cc2c1cccc2F YXISLLAVLYFJLK-UHFFFAOYSA-N 0.000 description 1
- VUHRPUFFLVNHPZ-UHFFFAOYSA-N CC(C)Oc1cc(CCC(C)(C)N(C2)Cc3c2cccc3F)ccc1N=O Chemical compound CC(C)Oc1cc(CCC(C)(C)N(C2)Cc3c2cccc3F)ccc1N=O VUHRPUFFLVNHPZ-UHFFFAOYSA-N 0.000 description 1
- CZMKZNSLFDBBJT-UHFFFAOYSA-N CC(C)Oc1cc(CCC(C)(C)N(Cc2ccc3)Cc2c3F)ccc1O Chemical compound CC(C)Oc1cc(CCC(C)(C)N(Cc2ccc3)Cc2c3F)ccc1O CZMKZNSLFDBBJT-UHFFFAOYSA-N 0.000 description 1
- VFTROENQUWUAES-GOSISDBHSA-N CC(C)Oc1ccc(CC[C@@H](C)N(Cc2ccc3)Cc2c3F)cc1OC(C)C Chemical compound CC(C)Oc1ccc(CC[C@@H](C)N(Cc2ccc3)Cc2c3F)cc1OC(C)C VFTROENQUWUAES-GOSISDBHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934528P | 2014-01-31 | 2014-01-31 | |
| US61/934,528 | 2014-01-31 | ||
| PCT/US2015/013754 WO2015116923A1 (en) | 2014-01-31 | 2015-01-30 | Isoindoline compositions and methods for treating neurodegenerative disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507122A JP2017507122A (ja) | 2017-03-16 |
| JP2017507122A5 JP2017507122A5 (OSRAM) | 2018-03-08 |
| JP6517827B2 true JP6517827B2 (ja) | 2019-05-22 |
Family
ID=53757753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016549224A Active JP6517827B2 (ja) | 2014-01-31 | 2015-01-30 | イソインドリン組成物および神経変性疾患の治療方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US9796672B2 (OSRAM) |
| EP (3) | EP3498692B1 (OSRAM) |
| JP (1) | JP6517827B2 (OSRAM) |
| KR (1) | KR102331422B1 (OSRAM) |
| CN (1) | CN106163516B (OSRAM) |
| AU (1) | AU2015210852B2 (OSRAM) |
| BR (1) | BR112016017808B1 (OSRAM) |
| CA (1) | CA2938212C (OSRAM) |
| DK (2) | DK3099296T3 (OSRAM) |
| ES (2) | ES2915833T3 (OSRAM) |
| IL (1) | IL247003B (OSRAM) |
| MX (1) | MX368755B (OSRAM) |
| NZ (1) | NZ722599A (OSRAM) |
| RU (1) | RU2692258C2 (OSRAM) |
| WO (1) | WO2015116923A1 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106957282B (zh) | 2011-12-21 | 2019-08-30 | 诺维拉治疗公司 | B型肝炎抗病毒剂 |
| AR092270A1 (es) | 2012-08-28 | 2015-04-08 | Janssen R&D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| ES2628953T3 (es) | 2013-02-28 | 2017-08-04 | Janssen Sciences Ireland Uc | Sulfamoilarilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis B |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| PL3024819T3 (pl) | 2013-07-25 | 2018-08-31 | Janssen Sciences Ireland Uc | Pochodne piroloamidowe podstawione glioksamidem i ich zastosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B |
| SG11201602748XA (en) | 2013-10-23 | 2016-05-30 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| DK3099296T3 (en) | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| KR20160128305A (ko) | 2014-02-05 | 2016-11-07 | 노비라 테라퓨틱스, 인코포레이티드 | Hbv 감염의 치료를 위한 병용 요법 |
| ES2705401T3 (es) | 2014-02-06 | 2019-03-25 | Janssen Sciences Ireland Uc | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la Hepatitis B |
| EP3271019A1 (en) | 2015-03-19 | 2018-01-24 | Novira Therapeutics Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| JP6845231B2 (ja) | 2015-09-29 | 2021-03-17 | ノヴィラ・セラピューティクス・インコーポレイテッド | Ｂ型肝炎抗ウイルス薬の結晶形態 |
| US11046670B2 (en) | 2015-10-19 | 2021-06-29 | Board Of Regents, The University Of Texas System | Piperazinyl norbenzomorphan compounds and methods for using the same |
| KR20180129943A (ko) | 2016-04-15 | 2018-12-05 | 노비라 테라퓨틱스, 인코포레이티드 | 캡시드 조립 억제제를 포함하는 배합물 및 방법 |
| EP3448520A4 (en) * | 2016-04-29 | 2020-07-29 | Board Of Regents, The University Of Texas System | SIGMA RECEIVER BINDERS |
| CN107162944B (zh) * | 2017-04-27 | 2019-02-26 | 湖南化工研究院有限公司 | 2,3-二甲基苯甲硫醚的制备方法 |
| KR102614814B1 (ko) | 2017-05-15 | 2023-12-20 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 신경변성 질환 치료용 조성물 |
| EP3704092A4 (en) * | 2017-11-01 | 2021-08-25 | Cognition Therapeutics, Inc. | ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE |
| EP3765011A1 (en) | 2018-03-14 | 2021-01-20 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| JP6567153B1 (ja) * | 2018-09-28 | 2019-08-28 | 学校法人東北工業大学 | 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム |
| US20220009876A1 (en) * | 2018-10-31 | 2022-01-13 | Polycore Therapeutics Llc | Method for synthesizing d3 dopamine receptor agonists |
| MA55020A (fr) | 2019-02-22 | 2021-12-29 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| CN109734639B (zh) * | 2019-03-08 | 2020-10-09 | 漯河市卫龙生物技术有限公司 | 一种食用香精香料的制备方法 |
| CN109734638A (zh) * | 2019-03-08 | 2019-05-10 | 新昌县大船畈生物科技有限公司 | 一种食用香精香料的制备方法 |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CN112694427B (zh) * | 2019-10-23 | 2022-11-18 | 江西天宇化工有限公司 | 一种制备2,3-二甲基苯甲硫醚的方法 |
| WO2021163613A1 (en) * | 2020-02-13 | 2021-08-19 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
| EP4153209A1 (en) | 2020-05-20 | 2023-03-29 | The Board of Trustees of the University of Illinois | Method for treating lysosomal storage diseases with histatin peptides |
| MX2023006677A (es) * | 2020-12-11 | 2023-06-27 | Cognition Therapeutics Inc | Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). |
| KR20230159546A (ko) * | 2021-03-19 | 2023-11-21 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 신경학적 질환을 치료하기 위한 조성물 및 방법 |
| US20250177351A1 (en) * | 2022-07-18 | 2025-06-05 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| WO2024130030A1 (en) * | 2022-12-14 | 2024-06-20 | Fred Hutchinson Cancer Center | Method for treating neurological diseases through glial pruning regulation |
| WO2024196799A2 (en) * | 2023-03-17 | 2024-09-26 | Cognition Therapeutics, Inc. | Isoindoline compositions and methods for treating neurodegenerative disease |
| CN117945980A (zh) * | 2024-01-24 | 2024-04-30 | 上海健康医学院 | 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA732136B (en) | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
| DE2753278A1 (de) | 1977-11-30 | 1979-05-31 | Basf Ag | Aralkylpiperidinone |
| US4321386A (en) | 1981-01-28 | 1982-03-23 | Mead Johnson & Company | Quaternary piperidinium halides |
| DE3222152A1 (de) | 1982-06-12 | 1983-12-15 | Bayer Ag, 5090 Leverkusen | Substituierte maleinsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
| IL70813A (en) | 1983-01-31 | 1987-10-30 | Lilly Co Eli | Animal feed comprising certain phenethanolamine derivatives and 1-phenyl-2-(1-methyl-3-(4-nitrophenyl)propylamino)ethanol hydrochloride |
| JPS62283922A (ja) | 1986-05-30 | 1987-12-09 | Tsumura Juntendo Inc | 血小板凝集抑制剤 |
| US4697024A (en) | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
| US4958029A (en) * | 1987-01-13 | 1990-09-18 | Banyu Pharmaceutical Co., Ltd. | Process for the production of isoindoline derivatives, novel intermediates and process for their production |
| JPH01180822A (ja) | 1988-01-12 | 1989-07-18 | Dainippon Pharmaceut Co Ltd | 抗遅延型アレルギー剤 |
| JPH01305085A (ja) | 1988-05-31 | 1989-12-08 | Yamanouchi Pharmaceut Co Ltd | ピリジルチアゾリジンカルボン酸アミド誘導体 |
| JPH02215789A (ja) | 1989-02-15 | 1990-08-28 | Yamanouchi Pharmaceut Co Ltd | チアゾロ［３，４―ａ］ピラジン誘導体 |
| AU658134B2 (en) | 1989-12-28 | 1995-04-06 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| DE4000610A1 (de) | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
| JP2818958B2 (ja) | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法 |
| JPH045266A (ja) | 1990-04-24 | 1992-01-09 | Toyo Pharma- Kk | ドパミン誘導体の製造方法 |
| DE4142366A1 (de) | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| WO1995011221A1 (en) | 1991-08-23 | 1995-04-27 | Nps Pharmaceuticals, Inc. | Calcium receptor-active arylalkyl amines |
| US6610493B1 (en) | 1993-06-17 | 2003-08-26 | Brigham And Women's Hospital | Screening compounds for the ability to alter the production of amyloid-β peptide |
| CA2115900A1 (en) | 1993-02-22 | 1994-08-23 | Gerald W. Becker | Pharmaceutical screens and antibodies |
| JPH06321781A (ja) | 1993-05-13 | 1994-11-22 | Yamanouchi Pharmaceut Co Ltd | 血小板活性化因子拮抗剤 |
| DE69535461T2 (de) | 1994-10-21 | 2008-09-25 | NPS Pharmaceuticals, Inc., Salt Lake City | Kalzium-rezeptor aktive verbindungen |
| JPH0915744A (ja) | 1995-06-29 | 1997-01-17 | Fuji Photo Film Co Ltd | 磁気ヘッドの検査方法及びフィルムキャリア |
| JP3522930B2 (ja) | 1995-12-06 | 2004-04-26 | 花王株式会社 | 抗菌剤及びこれを含有する口腔用組成物 |
| WO1997030038A1 (en) | 1996-02-15 | 1997-08-21 | Mitsubishi Chemical Corporation | Diarylsultam derivatives |
| KR19990087814A (ko) | 1996-04-24 | 1999-12-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 과지방혈증 방지제로서의 융합 이미다조피리딘유도체 |
| US6218506B1 (en) | 1997-02-05 | 2001-04-17 | Northwestern University | Amyloid β protein (globular assembly and uses thereof) |
| US6518315B1 (en) | 1997-10-21 | 2003-02-11 | The University Of Sydney | Medicinal uses of phenylaikanols and derivatives |
| CO4980891A1 (es) | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
| CO5011072A1 (es) | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
| IL138686A0 (en) | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| AU2300001A (en) | 1999-10-22 | 2001-05-08 | Board Of Trustees Of The University Of Illinois, The | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| DE10027151A1 (de) | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| ATE513043T1 (de) | 2001-03-05 | 2011-07-15 | Yissum Res Dev Co | Gegen denaturierungsmittel stabile und/oder proteaseresistente, chaperonähnliche oligomere proteine, diese kodierende polynukleotide sowie ihre verwendungen |
| JP4312402B2 (ja) | 2001-07-31 | 2009-08-12 | 有限会社大長企画 | 抗うつ剤、抗更年期障害剤、抗老人性痴呆症剤、抗アルツハイマー剤 |
| AU2002332659A1 (en) | 2001-08-21 | 2003-03-03 | Sepracor, Inc. | 2-substituted piperidines that are ligands for monoamine receptors and transporters |
| US6991814B2 (en) | 2001-12-13 | 2006-01-31 | Council Of Scientific And Industrial Research | Herbal medicaments for the treatment of neurocerebrovascular disorders |
| GEP20084442B (en) | 2001-12-14 | 2008-08-10 | Council Scient Ind Res | Compositions for the treatment of neurocerebrovascular disorders |
| JP2004002517A (ja) | 2002-05-31 | 2004-01-08 | Dae Sil Kim | 生姜成分を含む石鹸の組成物及びその製造方法 |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| DE10320560A1 (de) | 2003-05-07 | 2004-01-29 | Brosig, Stefan, Dr. | Mittel zur Bekämpfung der Alzheimer Erkrankung und/oder der Parkinson Krankheit |
| US7829562B2 (en) | 2003-06-12 | 2010-11-09 | M's Science Corporation | Sigma ligands for neuronal regeneration and functional recovery |
| EP1644026A4 (en) | 2003-06-12 | 2007-10-24 | Ms Science Corp | SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECREATION |
| HRP20060326A2 (hr) | 2004-03-12 | 2007-02-28 | Egis Gy�gyszergy�r Nyrt. | Kombinirani farmaceutski kompozit za inhibiciju pada kognitivnih funkcija |
| JPWO2005115366A1 (ja) | 2004-05-31 | 2008-03-27 | 株式会社カネカ | ウコン精油成分を含有する生活習慣病予防・改善剤 |
| ES2415665T3 (es) | 2004-06-21 | 2013-07-26 | Proteome Sciences Plc | Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau |
| TW200613272A (en) | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| US20080153917A1 (en) | 2004-09-10 | 2008-06-26 | Ucb Pharma, S.A. | Sigma Receptor Ligands |
| US20080044356A1 (en) | 2004-10-22 | 2008-02-21 | Regents Of The University Of Minnesota | Assemblies of Oligomeric Amyloid Beta Protein and Uses Thereof |
| WO2006066118A2 (en) | 2004-12-15 | 2006-06-22 | Neuralab Limited | Contextual fear test for predicting efficacy of alzheimer immunotherapeutic treatment |
| EP2204381A1 (en) | 2005-03-05 | 2010-07-07 | Abbott GmbH & Co. KG | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| CA2611489A1 (en) | 2005-06-15 | 2006-12-28 | Darrick S.H.L. Kim | Synergistic pharmaceutical compositions useful in prevention and treatment of beta-amyloid protein-induced disease including sage and rosemary derived compounds |
| TW200726774A (en) | 2005-06-30 | 2007-07-16 | Merck & Co Inc | Composition and method for producing stable amyloid beta oligomers |
| EP1745778A3 (en) | 2005-07-20 | 2007-03-07 | Speedel Experimenta AG | Diaminoalcohols as therapeutic compounds |
| ITRM20060007A1 (it) | 2006-01-05 | 2007-07-06 | Univ Bari | Recettore sigma-2 metodo di screening di ligandi specifici e uso degli stessi in metodi diagnostici o terapeutici |
| US20070218491A1 (en) | 2006-02-08 | 2007-09-20 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
| US20080193573A1 (en) | 2006-03-17 | 2008-08-14 | Gow Robert T | Extracts and methods comprising curcuma species |
| WO2007112288A2 (en) | 2006-03-23 | 2007-10-04 | Mount Sinai School Of Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
| WO2007126473A2 (en) | 2006-04-10 | 2007-11-08 | Oligomerix, Inc. | Oligomerization of amyloid proteins |
| WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
| US7561775B2 (en) | 2006-08-22 | 2009-07-14 | Senko Advanced Components, Inc. | Fiber optic protective shutter |
| EP2066692B1 (en) | 2006-09-08 | 2012-01-11 | VIB, vzw | Means and methods for the production of amyloid oligomers |
| US7723377B2 (en) | 2006-09-29 | 2010-05-25 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| US20080131233A1 (en) | 2006-10-17 | 2008-06-05 | Yao Chun I | Plate-shaped fastener device |
| WO2008076262A2 (en) | 2006-12-15 | 2008-06-26 | Merck & Co., Inc. | Receptor for amyloid beta and uses thereof |
| US20080171757A1 (en) | 2007-01-11 | 2008-07-17 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Serivces | Methods to identify inhibitors of cell sickling |
| EP2152744A4 (en) | 2007-04-26 | 2012-02-15 | Univ Yale | PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS |
| AU2008254905A1 (en) | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of treating cognitive disorders by inhibition of Gpr12 |
| CN101121670A (zh) | 2007-09-11 | 2008-02-13 | 上海紫源制药有限公司 | 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法 |
| WO2009048631A1 (en) | 2007-10-11 | 2009-04-16 | University Of Tennessee Research Foundation | PREPARATION OF PURIFIED COVALENTYLY CROSS-LINKED A β OLIGOMERS AND USES THEREOF |
| EP2206707B1 (en) | 2007-10-24 | 2014-07-23 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| US8168800B2 (en) | 2007-11-02 | 2012-05-01 | The Regents Of The University Of California | Aβ-binding small molecules |
| WO2009067493A2 (en) | 2007-11-19 | 2009-05-28 | Envivo Pharmaceuticals, Inc. | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders |
| CN102203124A (zh) | 2008-07-25 | 2011-09-28 | 雅培制药有限公司 | 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途 |
| KR101515822B1 (ko) | 2008-11-29 | 2015-04-29 | 더 타일랜드 리서치 펀드 | 바이러스와 타겟 세포의 상호작용 저해 |
| WO2010088450A2 (en) | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
| ES2742251T3 (es) | 2009-03-16 | 2020-02-13 | Pangu Biopharma Ltd | Composiciones y procedimientos que comprenden variantes de splicing de histidil-tarn sintetasa que tienen actividades biológicas no canónicas |
| US7972164B2 (en) | 2009-03-24 | 2011-07-05 | Tyco Electronics Corporation | Connector assembly with a latch |
| ES2545795T3 (es) * | 2009-04-09 | 2015-09-15 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
| WO2011012672A1 (en) | 2009-07-29 | 2011-02-03 | Pharnext | New diagnostic tools for alzheimer disease |
| BR112012002246A2 (pt) | 2009-07-31 | 2019-09-24 | Cognition Therapeutics Inc | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente |
| US20150160228A1 (en) | 2010-02-05 | 2015-06-11 | Susan Catalano | Compositions and method for determining the efficacy of amyloidosis treatments |
| WO2011106785A2 (en) | 2010-02-26 | 2011-09-01 | Cognition Therapeutics, Inc. | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| WO2012027548A1 (en) | 2010-08-25 | 2012-03-01 | The Feinstein Institute For Medical Research | Compounds and methods for prevention and treatment of alzheimer's and other diseases |
| US20170049723A1 (en) | 2011-02-02 | 2017-02-23 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| SG192596A1 (en) | 2011-02-02 | 2013-09-30 | Cognition Therapeutics Inc | Isolated compounds from turmeric oil and methods of use |
| EP2747768A4 (en) | 2011-08-25 | 2015-10-21 | Cognition Therapeutics Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| HK1202248A1 (en) * | 2011-08-25 | 2015-09-25 | 考格尼申治疗股份有限公司 | Compositions and methods for treating neurodegenerative disease |
| AT511906B1 (de) | 2011-08-30 | 2016-05-15 | Blum Gmbh Julius | Schublade |
| WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
| DK3099296T3 (en) | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| KR102614814B1 (ko) | 2017-05-15 | 2023-12-20 | 카그니션 테라퓨틱스, 인코퍼레이티드 | 신경변성 질환 치료용 조성물 |
| EP3704092A4 (en) * | 2017-11-01 | 2021-08-25 | Cognition Therapeutics, Inc. | ISOINDOLINE COMPOSITIONS AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASE |
| CN110283082A (zh) | 2019-07-15 | 2019-09-27 | 泰州职业技术学院 | 一种3-苯基丙胺的制备方法 |
| WO2021163613A1 (en) | 2020-02-13 | 2021-08-19 | Cognition Therapeutics, Inc. | Method of decreasing amyloid beta monomer levels in patients with cognitive decline |
| MX2023006677A (es) | 2020-12-11 | 2023-06-27 | Cognition Therapeutics Inc | Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). |
-
2015
- 2015-01-30 DK DK15743281.6T patent/DK3099296T3/en active
- 2015-01-30 ES ES19154222T patent/ES2915833T3/es active Active
- 2015-01-30 AU AU2015210852A patent/AU2015210852B2/en active Active
- 2015-01-30 EP EP19154222.4A patent/EP3498692B1/en active Active
- 2015-01-30 ES ES15743281T patent/ES2721001T3/es active Active
- 2015-01-30 US US15/115,187 patent/US9796672B2/en active Active
- 2015-01-30 EP EP22155541.0A patent/EP4023294A1/en active Pending
- 2015-01-30 NZ NZ722599A patent/NZ722599A/en unknown
- 2015-01-30 MX MX2016009845A patent/MX368755B/es active IP Right Grant
- 2015-01-30 KR KR1020167023951A patent/KR102331422B1/ko active Active
- 2015-01-30 RU RU2016134677A patent/RU2692258C2/ru active
- 2015-01-30 DK DK19154222.4T patent/DK3498692T3/da active
- 2015-01-30 EP EP15743281.6A patent/EP3099296B1/en active Active
- 2015-01-30 CN CN201580017497.0A patent/CN106163516B/zh active Active
- 2015-01-30 CA CA2938212A patent/CA2938212C/en active Active
- 2015-01-30 JP JP2016549224A patent/JP6517827B2/ja active Active
- 2015-01-30 BR BR112016017808-4A patent/BR112016017808B1/pt active IP Right Grant
- 2015-01-30 WO PCT/US2015/013754 patent/WO2015116923A1/en not_active Ceased
-
2016
- 2016-07-28 IL IL247003A patent/IL247003B/en active IP Right Grant
-
2017
- 2017-09-11 US US15/700,923 patent/US10207991B2/en active Active
-
2018
- 2018-12-21 US US16/230,238 patent/US10611728B2/en active Active
-
2020
- 2020-02-06 US US16/783,943 patent/US11691947B2/en active Active
-
2023
- 2023-04-27 US US18/308,037 patent/US12466795B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6517827B2 (ja) | イソインドリン組成物および神経変性疾患の治療方法 | |
| JP2017206545A (ja) | 神経変性疾患を処置する組成物及び方法 | |
| JP2014529613A (ja) | 神経変性疾患を治療する組成物及び方法 | |
| US11981636B2 (en) | Compositions for treating neurodegenerative diseases | |
| HK40010047B (en) | Isoindoline compositions and methods for treating neurodegenerative disease | |
| HK40010047A (en) | Isoindoline compositions and methods for treating neurodegenerative disease | |
| HK1225651B (zh) | 异吲哚啉组合物和治疗神经变性疾病的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180129 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180129 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180927 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181009 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181226 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190402 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190418 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6517827 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |